Document is current
Any future updates will be listed below
-
Authors
Fleischmann, Roy https://orcid.org/0000-0002-6630-1477
Blanco, Ricardo
Van den Bosch, Filip https://orcid.org/0000-0002-3561-5932
Bessette, Louis
Song, Yanna
Penn, Sara K.
McDearmon-Blondell, Erin
Khan, Nasser
Chan, Kelly
Mysler, Eduardo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02629159 at ClinicalTrials.govDocuments that mention this clinical trial
POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE
https://doi.org/10.1136/annrheumdis-2024-eular.1416
FRI0089 COMPARATIVE EFFICACY (ACR 20) OF TOCILIZUMAB TO OTHER TARGETED IMMUNE MODULATORS (TIM) FOR RHEUMATOID ARTHRITIS: A NETWORK META-ANALYSIS (NMA)
https://doi.org/10.1136/annrheumdis-2020-eular.532
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
https://doi.org/10.1136/rmdopen-2023-004007
Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
https://doi.org/10.1136/rmdopen-2024-005371
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
https://doi.org/10.1136/annrheumdis-2019-215764
OP0225 EVALUATION OF RESPONSE TO ADJUVANTED RECOMBINANT ZOSTER VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A RANDOMIZED TRIAL SUB-STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2386
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
POS0643 ASSOCIATION OF EARLY REMISSION ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST-HOC ANALYSIS OF DATA FROM THE SELECT-COMPARE STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.1469
FRI0137 UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
https://doi.org/10.1136/annrheumdis-2019-eular.287
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2020-218412
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
https://doi.org/10.1136/rmdopen-2025-005521
Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
https://doi.org/10.1007/s40744-024-00658-1
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
OP0020 IMMUNOGENICITY OF AN ADJUVANT RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: 60-WEEK RESULTS FROM A RANDOMIZED SUBSTUDY
https://doi.org/10.1136/annrheumdis-2024-eular.763
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 21 February 2024
First Online: 18 March 2024
Declarations
:
: Roy Fleischmann has received consulting fees and/or grant/research support from AbbVie, Amgen, BI, Biosplice, BMS, DREN Bio, Flexion, Galapagos, Galvani, Genentech, Gilead, GSK, Horizon, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, Selecta, Teva, UCB, Viela, Vorso, and Vyne. Ricardo Blanco has received grant/research support from AbbVie, MSD, and Roche; and consulting fees/participated in speaker’s bureau from AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, and Roche. Filip Van den Bosch has received speaker and/or consulting fees from AbbVie, Amgen, BMS, Galapagos, Janssen, Lilly, Merck, Novartis, Sanofi, and UCB. Louis Bessette has received speaking fees, consulting fees, and grant/research support from AbbVie, Amgen, BMS, Celgene, Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Organon, Pfizer, Roche, Sanofi-Aventis, Teva, and UCB. Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, and Kelly Chan are employees of AbbVie and may hold stock or options. Eduardo Mysler has received speaking fees, consulting fees, and grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Hi-Bio, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, and Sanofi.
: This study is being conducted according to the International Council for Harmonization guidelines, local regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. All patients provided written informed consent, and the study protocol and consent forms were approved by an institutional review board or independent ethics committee at each study site. Approval was received from the master ethics committee, the Advarra Institutional Review Board (Pro00034396).
